[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangsu vcare pharmaceutical technology co., LTD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":219},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,63,83,106,125,144,165,181,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100651623","phase-1-a-phase-i-study-of-vc005-tablets-in-adolescent-subjects-with-severe-alopecia-areata-100651623",false,"NCT07762443","A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata","A Phase I Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata","Inclusion Criteria:\n\n* The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF).\n* Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 40 kg.\n* Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period.\n* Subjects with a current diagnosis of acute diffuse alopecia areata (AA).\n* Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc.\n* Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.","ALL","12 Years","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).",[27],"Alopecia Areata","NOT_YET_RECRUITING","2026-08-09",{"date":31,"type":32},"2026-08-13","ACTUAL",{"date":34,"type":21},"2026-09-30",{"date":36,"type":21},"2027-12-30",{"name":38,"class":39},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100650647","phase-2-phase-ii-clinical-study-of-vc005-tablets-in-subjects-with-severe-alopecia-areata-100650647","NCT07749716","Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata","Inclusion Criteria:\n\n* Subjects must fully understand the study, be willing and able to comply with all trial procedures, voluntarily participate in the clinical trial, and provide written informed consent by signing the informed consent form (ICF).\n* Subjects must be aged between 18 and 65 years (inclusive) at the time of ICF signing, regardless of gender.\n* Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period.\n* Subjects with a current diagnosis of acute diffuse alopecia areata (AA).\n* Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc.\n* Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.","65 Years",{"count":50,"type":21},120,[52],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).",[27],"2026-08-03",{"date":57,"type":32},"2026-08-06",{"date":59,"type":21},"2026-08-15",{"date":61,"type":21},"2028-12-30",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":81,"locationsCount":82},"100649113","phase-1-a-phase-ib-randomized-double-blind-placebo-controlled-study-to-evaluate-the-safety-and-efficacy-of-vc004-capsules-for-pain-in-bone-metastases-100649113","NCT07731685","A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases","Inclusion Criteria:\n\n1. Participants must understand and voluntarily sign the informed consent form (ICF);\n2. Male or female, aged ≥ 18 years;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;\n4. Life expectancy of ≥ 12 weeks, as assessed by the investigator;\n5. The participant is able to communicate well with the investigator, and is willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. The participant's pain is associated with oncologic emergencies, such as intestinal obstruction\u002Fperforation, spinal cord compression, epidural metastasis, or fracture or impending fracture of weight-bearing bones;\n2. The participant has known or suspected unstable brain metastases or leptomeningeal metastases；\n3. History of severe alcohol, analgesic, or narcotic drug abuse within 6 months prior to screening;\n4. Major surgery within 3 months prior to screening, or planned major surgery during the study period;\n5. Female participants who are planning to become pregnant, are pregnant, or are breastfeeding; or participants who are unwilling or unable to use effective contraception throughout the entire study period and for 3 months after the end of the study;\n6. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.",{"count":70,"type":21},26,[24],"This is a randomized, double-blind, placebo-controlled Phase Ib study evaluating the safety and efficacy of VC004 capsules for the relief of moderate-to-severe pain associated with bone metastases",[74],"Pain in Bone Metastases","2026-07-23",{"date":77,"type":32},"2026-07-28",{"date":79,"type":21},"2026-07-30",{"date":36,"type":21},{"name":38,"class":39},2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":40},"100571655","phase-3-phase-iii-clinical-study-of-vc005-tablets-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-100571655","NCT06723080","Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","Inclusion Criteria:\n\n(1）The patient understands and voluntarily signs the Informed Consent Form (ICF), and has the willingness and ability to complete the regular visits,treatment plans, laboratory tests and other experimental procedures required by the program. (2) Male or female patients aged ≥18 and ≤75 years at the time of signing the ICF. (3) Meet Hanifin-Rajka diagnostic criteria at screening and have atopic dermatitis （AD) symptoms for at least 1 year prior to baseline. (4) At screening and baseline, meets criteria for moderately severe AD based on the investigator's assessment of 3 of the following:Eczema area and severity index (EASI) score ≥12;Psoriasis Area Severity Index (IGA) score ≥3;AD involvement in ≥10% of the Body Surface Area (BSA). (5) Recent (within 1 year prior to screening) topical treatment for AD with inadequate or intolerant clinical response, as determined by the investigator\n\nExclusion Criteria:\n\n(1) Inability to swallow the test drug or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunt, or the presence of a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome) or other malabsorption condition that interferes with the absorption of the drug; (2) Current or history of lymphoproliferative disorders or presence of signs or symptoms suggestive of possible lymphoproliferative disorders of lymphoid tissue, including lymphadenopathy or splenomegaly; malignancies of any kind, or a history of any malignancy within the 5 years prior to Screening (except for completely resected carcinoma in situ of the cervix or non-metastatic squamous cell or basal cell carcinoma of the skin or papillary carcinoma of the thyroid gland); (3) Patients with prior thromboembolism (including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc.) or other high-risk groups prone to thromboembolism; (4) Patients with a history of herpes virus infection within the last 1 month or those with recurrent episodes of herpes zoster (≥2), disseminated herpes zoster, disseminated herpes simplex, or those for whom herpes zoster or herpes simplex infections cannot be excluded at this time;","75 Years",{"count":92,"type":21},480,[94],"PHASE3","This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study",[97],"Moderate to Severe Atopic Dermatitis","RECRUITING",{"date":100,"type":32},"2026-07-27",{"date":102,"type":32},"2024-12-30",{"date":104,"type":21},"2027-08-30",{"name":38,"class":39},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100566682","phase-3-phase-iii-clinical-study-of-vc004-in-patients-with-localized-advanced-metastatic-solid-tumors-100566682","NCT06658353","Phase III Clinical Study of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Inclusion Criteria:\n\n* All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；\n* Male or female, age ≥12 years old;\n\nExclusion Criteria:\n\n* Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);\n* Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);\n* Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.",{"count":114,"type":21},54,[94],"This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced\u002Fmetastatic solid tumors.",[118],"Locally Advanced Solid Tumor",{"date":100,"type":32},{"date":121,"type":32},"2025-03-17",{"date":123,"type":21},"2026-12-30",{"name":38,"class":39},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":143,"locationsCount":40},"100560467","phase-3-efficacy-and-safety-study-of-vicagrel-in-patients-with-acute-coronary-syndrome-acs-undergoing-percutaneous-coronary-intervention-pci-100560467","NCT06577519","Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial","Inclusion Criteria:\n\n* Patients between 18 and 80 years old, with no gender restrictions.\n* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA\u002FNSTEMI).\n* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.\n\nExclusion Criteria:\n\n* Expected survival time\\\u003C12 months;\n* Severe liver dysfunction (non heart disease induced ALT or AST\\>3x ULN) and cirrhosis;\n* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;\n* The researchers determined that other reasons were not suitable for participants in this experiment.","80 Years",{"count":134,"type":21},1000,[94],"This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.",[138],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)",{"date":100,"type":32},{"date":141,"type":32},"2024-09-06",{"date":123,"type":21},{"name":38,"class":39},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":40},"100640383","phase-3-phase-iii-clinical-study-of-vc005-in-adult-and-adolescents-with-mild-to-moderate-atopic-dermatitis-100640383","NCT07592585","Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis","Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis","Inclusion Criteria:\n\n1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);\n2. The age requirement for signing the ICF is 12 years old or above, with no gender restrictions;\n3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.\n\nExclusion Criteria:\n\n1. Patients whose AD course is judged by the investigator as unstable(spontaneous improvement or rapid worsening) within 2 weeks prior to baseline;\n2. At screening and baseline, lesions are localized only to the hands or feet, with no prior history of involvement of other typical areas (such as the face or flexural areas);\n3. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., pigmentation, extensive scarring, tattoos, etc., at the affected area);\n4. At screening and baseline, presence of skin diseases that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton syndrome, etc.",{"count":152,"type":21},360,[94],"A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis",[156],"Atopic Dermatitis","2026-07-03",{"date":159,"type":32},"2026-07-07",{"date":161,"type":32},"2026-05-12",{"date":163,"type":21},"2028-05-30",{"name":38,"class":39},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":40},"100640312","phase-2-a-multicenter-randomized-double-blind-vehicle-controlled-phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-vc005-gel-in-adult-subjects-with-mild-to-moderate-atopic-dermatitis-100640312","NCT07598383","A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis","Inclusion Criteria:\n\n1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);\n2. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;\n3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.\n\nExclusion Criteria:\n\n1. Patients judged by the investigator to have an unstable course of Atopic Dermatitis (AD) (spontaneous improvement or rapid deterioration) within 2 weeks before baseline;\n2. Patients with skin lesions limited to the hands or feet at screening and baseline, with no prior history of involvement in other typical areas (such as the face or flexural folds);\n3. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., hyperpigmentation, large-area scars, tattoos, etc. at the affected site);\n4. Presence of skin diseases at screening and baseline that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton's syndrome, etc.;\n5. Patients with a history of malignant tumors, with the exception of: cervical carcinoma in situ, non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma, or non-metastatic papillary thyroid carcinoma that have been completely resected with no evidence of recurrence for more than 5 years of survival.",{"count":50,"type":21},[52],"This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis",[156],{"date":159,"type":32},{"date":177,"type":32},"2026-06-01",{"date":179,"type":21},"2027-02-22",{"name":38,"class":39},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":40},"100606192","phase-3-efficacy-and-safety-phase-iii-clinical-study-of-vc005-tablets-in-subjects-with-active-ankylosing-spondylitis-100606192","NCT07172360","Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;\n* The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;\n* The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis\n\nExclusion Criteria:\n\n* Those who may be allergic to VC005, similar drugs or their excipients.\n* Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.\n* Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.","70 Years",{"count":190,"type":21},420,[94],"This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.",[194],"Active Ankylosing Spondylitis","2025-12-29",{"date":197,"type":32},"2026-01-02",{"date":199,"type":32},"2025-12-26",{"date":104,"type":21},{"name":38,"class":39},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":90,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":40},"100606191","phase-2-efficacy-and-safety-phase-ii-study-of-vc005-tablets-in-subjects-with-non-segmental-vitiligo-100606191","NCT07172347","Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.\n* The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.\n* All hair in the vitiligo area on the face is white.\n* Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.\n* Subjects who have previously received depigmentation treatment.\n* Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.",{"count":50,"type":21},[52],"This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study",[213],"Non-segmental Vitiligo",{"date":197,"type":32},{"date":216,"type":32},"2025-10-31",{"date":104,"type":21},{"name":38,"class":39},""]